SciSparc takes a major step forward with the filing of an IND application to the FDA for a Phase IIb clinical trial for the treatment of Tourette syndrome

The Yale Child Study Center of the Yale School of Medicine in the USA, the Hannover Medical School in Germany and the Tel Aviv Sourasky Medical Center in Israel are participating in the study.

TEL AVIV, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a clinical-stage specialty pharmaceutical company focused on developing therapies to treat central nervous system disorders and rare diseases, has taken a major step forward with its proprietary SCI-110 for the treatment of Tourette Syndrome (“TS”) by submitting an Investigational New Drug Application to the U.S. Food and Drug Administration for its Phase IIb clinical trial, as previously announced on August 23, 2024.